Aridis Pharmaceuticals (Nasdaq: ARDS) announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care (SOC) antibiotics for the treatment of pneumonia caused by Gram-positive bacteria Staphylococcus aureus (S. aureus) in mechanically ventilated hospitalized patients.

Digital Ally (Nasdaq: DGLY) and Clover Leaf Capital Corp. (Nasdaq: CLOE), a publicly traded special purpose acquisition company (SPAC), announced that Kustom Entertainment, Inc. (“Kustom Entertainment”), a wholly-owned subsidiary of Digital Ally focused on live events, concert production and ticketing, and CLOE have entered into a merger agreement. The transaction is expected to provide Kustom Entertainment with the ability to be a stand-alone entity with a focus and mission to own and produce events, festivals, and entertainment alongside its evolving primary and secondary ticketing technologies. Digital Ally will remain an independent public company following the merger.

Inspira Technologies (Nasdaq: IINN), a company aiming to revolutionize acute respiratory care, has announced the appointment of Dr. Adi Rizansky Nir, PhD to the position of Chief Medical Officer. Dr. Nir brings a wealth of expertise and a distinguished track record in the field of medicine and healthcare administration to the Company.

SPI Energy (Nasdaq: SPI), a global renewable energy company and provider of solar, storage and electric vehicle (EV) solutions for business, residential, government, logistics and utility customers, announced its wholly owned Solar4america subsidiary began construction of a new state-of-the-art 500MW n-type TOPCon solar cell manufacturing facility in the United States.